Page last updated: 2024-11-04

vorinostat and Weight Loss

vorinostat has been researched along with Weight Loss in 2 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Weight Loss: Decrease in existing BODY WEIGHT.

Research Excerpts

ExcerptRelevanceReference
"Vorinostat was administered at the assigned dosage level (100-400 mg, three times weekly) in a standard 3 + 3 dose escalation design."2.90A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. ( Agrawal, A; Baiocchi, R; Blakaj, D; Carrau, R; Diavolitsis, V; Grecula, J; Kang, S; Kumar, B; Kumar, P; Old, MO; Ozer, E; Palettas, M; Pan, Q; Rocco, J; Savvides, P; Teknos, TN; Wei, L, 2019)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Teknos, TN1
Grecula, J1
Agrawal, A1
Old, MO1
Ozer, E1
Carrau, R1
Kang, S1
Rocco, J1
Blakaj, D1
Diavolitsis, V1
Kumar, B1
Kumar, P1
Pan, Q1
Palettas, M1
Wei, L1
Baiocchi, R1
Savvides, P1
Yalon, M1
Tuval-Kochen, L1
Castel, D1
Moshe, I1
Mazal, I1
Cohen, O1
Avivi, C1
Rosenblatt, K1
Aviel-Ronen, S1
Schiby, G1
Yahalom, J1
Amariglio, N1
Pfeffer, R1
Lawrence, Y1
Toren, A1
Rechavi, G1
Paglin, S1

Trials

1 trial available for vorinostat and Weight Loss

ArticleYear
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
    Investigational new drugs, 2019, Volume: 37, Issue:4

    Topics: Anemia; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Drug Eruptions; Female; Head and Neck N

2019

Other Studies

1 other study available for vorinostat and Weight Loss

ArticleYear
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; Carrier Prot

2016